U.S. Healthtech Stock News

Ulta Beauty (NasdaqGS:ULTA) is expanding its K-Beauty World platform, giving viral Korean beauty brands faster access to the U.S. market. The company is doubling the number of e-commerce fulfillment stores and using AI tools to manage online orders and inventory. Brands that gain traction online, such as Dr. Melaxin, are moving quickly into nationwide in-store distribution across Ulta's network. Ulta Beauty operates as a multi brand beauty retailer, combining cosmetics, skincare, haircare,...

This article examines whether Compass at US$6.84 may represent attractive value or a potential value trap by exploring what the current price could be implying about the business. The stock has come under pressure recently, with a 19.2% decline over the last 7 days, 29.8% over 30 days, 34.9% year to date, and 21.6% over the past year, following a very large 3-year gain of 110.5% and a 5-year decline of 63.2%. Recent coverage has highlighted Compass as a real estate platform operating in a...

Wondering whether Viasat at around US$43.72 is still offering value or if most of the opportunity is already priced in? This article breaks down what the current share price might be implying. The stock has returned 16.2% year to date and 319.6% over the past year, even though the last 7 days and 30 days show declines of 11.1% and 4.5% respectively. Recent headlines have focused on Viasat's position in satellite communications and its role in providing connectivity services, which has kept...

If you are wondering whether Vistra's share price still reflects good value after its long run, or if the best days are already priced in, this article walks you through what the numbers say. The stock last closed at US$147.54, with returns showing a 2.5% decline over 7 days, a 15.2% decline over 30 days, a 10.7% decline year to date, and a 26.3% gain over the past year. The 3-year return is very large and the 5-year return is also very large. Recent moves in the share price have put more...

Silicon Motion Technology (SIMO) has drawn investor attention after recent price volatility, with the stock down about 18% over the past month but up roughly 17% in the past 3 months. See our latest analysis for Silicon Motion Technology. The recent 1 day share price decline of 4.19% and 7 day share price return of negative 14.77% sit against a much stronger 1 year total shareholder return of 113.94%. This suggests momentum has cooled in the short term after a powerful longer term run. If...

Array Technologies (ARRY) has been drawing attention after recent share price swings, with the stock at $6.88 and mixed returns across different periods, including a decline over the past 3 months and a 1-year total return above 40%. See our latest analysis for Array Technologies. The recent 1-day share price return of a 6.14% decline and 90-day share price return of a 26.81% decline contrast with a 1-year total shareholder return of 41.27%, suggesting earlier momentum has cooled in the short...

Bitmine Immersion Technologies (NYSEAM:BMNR) has expanded its MAVAN staking platform through the acquisition of the Pier Two infrastructure site. The move adds new validator infrastructure designed to support institutional scale Ethereum staking. This development goes beyond the initial MAVAN launch and ETH accumulation previously reported by the company. For you as an investor, this Pier Two acquisition moves NYSEAM:BMNR further into the Ethereum staking infrastructure business, with MAVAN...

Why Corning (GLW) is Back on Investors’ Radar Corning (GLW) has caught investor attention after a strong past 3 months, with a total return above 44%, even as the stock showed a 14% decline over the past month. See our latest analysis for Corning. The recent pullback in Corning’s share price, with a 1 month share price return of 15% and a 1 day move of 6% lower to US$128.55, follows a much stronger run earlier in the year. This included a 90 day share price return of 44.7% and a very large 1...

T. Rowe Price and Oak Hill Advisors recently launched the T. Rowe Price OHA Flexible Credit Income Fund (OFLEX), a publicly offered interval fund that invests across private and public credit markets and offers daily purchases with quarterly repurchase offers of at least 5% of outstanding shares at NAV. Alongside OFLEX, T. Rowe Price expanded its global retirement leadership team following a senior retirement executive’s planned exit, underscoring its focus on retirement solutions and...

In March 2026, Match Group agreed to settle a U.S. Federal Trade Commission lawsuit alleging OkCupid shared millions of users’ photos, demographic details, and location data with facial-recognition firm Clarifai in 2014 without proper disclosure, and must now certify stricter privacy compliance. The settlement underscores how data-handling practices and user privacy safeguards can directly influence regulatory risk, brand trust, and long-term platform engagement for Match Group’s...

If you are wondering whether Roku's current share price reflects its true worth, you are not alone; the stock's recent moves have raised fresh questions about what you are really paying for. Roku closed at US$88.23, with returns of a 9.8% decline over 7 days, a 10.3% decline over 30 days and an 18.8% decline year to date, set against a 25.3% gain over 1 year and 34.3% over 3 years, while the 5 year return stands at a 73.1% decline. Recent headlines around Roku have focused on its position in...

If you are wondering whether Alphatec Holdings at around US$11 is a bargain or a value trap, the key is to look past the headline share price and into how it stacks up on valuation. The stock has seen a 9.5% decline over the last week, a 19.2% decline over the last 30 days, and is down 47.0% year to date, even though the 1 year return sits at 8.5%. These moves sit against a backdrop of ongoing interest in medical equipment companies, with investors weighing up growth potential in specialist...

In March 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic to identify esophageal or gastroesophageal junction carcinoma patients (CPS = 1) who may be eligible for Merck’s KEYTRUDA (pembrolizumab) combination therapy. This eighth KEYTRUDA-related indication for PD-L1 IHC 22C3 pharmDx strengthens Agilent’s role in precision oncology by broadening its companion diagnostic...

Box (BOX) has expanded its equity buyback plan, adding US$500 million in authorization to reach US$1.86b and extending the program through September 30, 2027. This move refocuses attention on capital returns. See our latest analysis for Box. At a share price of US$23.32, Box has a 90 day share price return of 23.31% and a one year total shareholder return of 24.43% decline, pointing to fading momentum even as the larger buyback program draws fresh attention from investors. If you are weighing...

With U.S. Bancorp around US$50.88, you might be wondering whether the current share price reflects solid value or if expectations have already been priced in. Over shorter periods the stock has been choppy, with a 1.2% decline over the last week and a 6.9% decline over the past month, while still showing a 25.6% return over 1 year and 64.2% over 3 years. Recent coverage has focused on how U.S. Bancorp fits into the broader U.S. banking sector and how investors are weighing interest rate...

Executive transition and business backdrop at Remitly Global Remitly Global (RELY) has drawn fresh attention after outlining a planned Chief Accounting Officer transition alongside recent gains in active customers and free cash flow margins, a mix that keeps investors focused on execution. See our latest analysis for Remitly Global. At a share price of US$15.32, Remitly’s 1 day share price return of 2.07% and 90 day share price return of 10.53%, alongside a 1 year total shareholder return...

GATX (GATX) has attracted attention after recent share price pressure, including an approximately 9% decline over the past month. This has prompted investors to reassess the railcar and engine leasing company’s fundamentals and valuation. See our latest analysis for GATX. While the recent 9% one month share price decline has weighed on sentiment, GATX’s 1 year total shareholder return of about 9% and 3 year total shareholder return close to 60% show that the longer term picture has been...

Wondering if Bristol-Myers Squibb at around US$59.73 is a bargain or a value trap? This article walks through the key signals that matter for you as a shareholder or potential investor. The stock is up 4.8% over the last week and 11.7% year to date. However, the 30-day return is a 4.2% decline and the one-year return sits at 2.9%, with a three-year return of a 1.7% decline and a five-year return of 14.4%. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has...

TSMC has started production of its next generation 2 nanometer process technology, marking a new step in advanced chip manufacturing. The company has raised its forward growth expectations, citing stronger than anticipated demand for AI related chips. These developments highlight TSMC's role in supplying cutting edge processors to major AI and cloud customers. For investors watching Taiwan Semiconductor Manufacturing, NYSE:TSM, the news arrives after a strong multi year share price run. The...

Wondering if National Energy Services Reunited at around US$20.81 is still offering value after its strong run, or if most of the opportunity has already been priced in. The stock has seen a 31.8% gain year to date and a very strong 182.7% return over the last year, although the past week and month show 5.1% and 16.9% declines that may be catching the eye of investors watching for a better entry point or shifting risk sentiment. Recent coverage has focused on how the market is reassessing...

Nektar Therapeutics presented new Phase 2b data for rezpegaldesleukin at the 2026 American Academy of Dermatology Annual Meeting. The data showed significant improvement in moderate to severe atopic dermatitis and severe to very severe alopecia areata. The company plans to start a Phase 3 program in atopic dermatitis following these results. Rezpegaldesleukin has received recent Fast Track designations from the FDA. Nektar Therapeutics (NasdaqCM:NKTR) is back in focus after sharing detailed...

Why Salesforce stock is drawing attention now Salesforce (CRM) is back on many investors’ screens after a choppy run, with the share price showing a 3.2% gain over the past day but negative returns over the month and past 3 months. See our latest analysis for Salesforce. That 3.2% 1 day share price return to US$185.03 comes after a weaker patch, with a 30.4% 3 month share price decline and a 30.6% 1 year total shareholder return decline suggesting momentum has been fading recently. If...

In March 2026, Sociedad Química y Minera de Chile S.A. reported that its Board had unanimously agreed to recommend a final dividend of 50% of 2025 net income, equivalent to US$1.03 per share, to be paid in Chilean pesos in May 2026 if approved at the April 23, 2026 shareholders’ meeting. This proposed uplift from the current 30% payout policy highlights a shift toward returning a larger share of earnings to investors, contingent on 2025 profitability. We’ll now examine how this proposed move...

If you are wondering whether XPeng's share price reflects its real worth, or if the market is mispricing the story, this article walks you through what the numbers are actually saying. XPeng's stock last closed at US$16.72, with returns of an 11.4% decline over 7 days, 4.8% decline over 30 days, 18.2% decline year to date and 19.3% decline over 1 year, set against a 52.0% gain over 3 years and 53.6% decline over 5 years. These mixed returns sit against a backdrop of ongoing headlines about...